Unfortunately I'm lazy too, so you may have to go digging a bit yourself . Also, what I find interesting, you may not. MT did say however that they expect the bio availability to be higher in the liquid formulation compared to the tablets, so it will need to go through PK studies before going into patients. IMO, this is good as less of the liquid will be needed, so less to have to swallow for the patient. There were a couple of answers re the FDA delay, but nothing really new there and one re the Elanco drug supply and that the New registered address is just a mailing address as we are a virtual company now which has staff based worldwide and is truly a 24/7 operation!
I've cut and pasted below what IMO was the best and most interesting reply to a question connected with engagement of the new CFO.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
. Also, what I find interesting, you may not.
(20min delay)